These payloads cause the cell to remove a protein that helps control gene activity. Antibody-linked versions have been tested in cancer cells and mice.
BRD4-directed heterobifunctional degraders recruit the cell's protein-disposal machinery rather than simply occupying an enzyme. Primary work demonstrated antigen-dependent BRD4 depletion and antitumor activity with degrader-antibody conjugates in mouse xenografts. This evidence supports antibody-mediated delivery of a degrader but does not establish that every intracellular protein can be reached or that a clinical therapeutic window follows from protein removal.
In plain words · BRD4 reads acetyl marks on DNA-packaging proteins and helps regulate transcription. Blocking a recognition pocket and removing the whole protein test different functions.
Showing the target this term concerns: BRD4.
Shares Degrader-antibody conjugate (DAC), Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Shares Next-generation antibody-conjugate payloads, Payload (ADC), Antibody-drug conjugate (ADC).
Every source this page cites, grouped by who published it. Grouping is read from the web address, not assigned by hand.
A source that has moved or gone is reported by the weekly link check. /audit/